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Abstract: The cysteinyl leukotrienes, LTC4, LTD4, and LTE4, play an integral role in the 
pathophysiology of asthma. Acting via the type 1 leukotriene (CysLT1) receptor, these proinﬂ  am-
matory mediators have numerous effects in the lungs, including decreased activity of respira-
tory cilia, increased mucus secretion, increased venopermeability, and promotion of eosinophil 
migration into airway mucosa. Blocking studies show that Cys-LTs are pivotal mediators in the 
pathophysiology of asthma. Cys-LTs are key components in the early and late allergic airway 
response and also contribute to bronchial obstruction after exercise and  hyperventilation of cold, 
dry air in asthmatics. Effects of the cysteinyl leukotrienes are blocked by leukotriene receptor 
antagonists; these agents inhibit bronchoconstriction in normal subjects provoked with inhaled 
cysteinyl leukotrienes, as well as in patients with asthma undergoing allergen, exercise, cold 
air, or aspirin challenge. Montelukast is a potent and selective blocker of the CysLT1 receptor. 
For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg 
ﬁ  lm-coated tablet, to children aged 6–14 years as a 5-mg chewable tablet, and to children aged 
2–5 years as a 4-mg chewable tablet form. Given their efﬁ  cacy, antiinﬂ  ammatory activity, oral 
administration, and safety, leukotriene modiﬁ  ers will play an important role in the treatment 
of asthmatic children.
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Introduction
Asthma is the most common chronic disease of childhood and its prevalence has 
substantially increased worldwide, particularly in pre-school children. It is associated 
with signiﬁ  cant morbidity and economic burden (Global Strategy for Asthma Manage-
ment and Prevention 1995, updated 2006). Chronic inﬂ  ammation and smooth muscle 
dysfunction are consistent features of asthma pathophysiology, responsible for disease 
progression and airway remodeling (National Heart Lung and Blood Institute 2002).
For more than two decades, no new drug has been introduced for asthma, and we 
have used the same old drugs in various dosage forms and combinations to give relief 
to the millions who suffer from this widespread illness (Mehta 2000). The two classes 
of drugs most commonly used for treating childhood asthma, namely the β2-agonist 
bronchodilators and inhaled corticosteroids, have both come under increasing scrutiny 
in the last few years. The development of tolerance resulting from continuous use 
of β2-agonists is of concern, as is the risk of adverse systemic effects with inhaled 
corticosteroids, particularly in children requiring high dosages. In addition, ensuring 
adequate compliance with inhaled therapy continues to be a major difﬁ  culty. Against 
this background, the development of an orally active, once-daily, disease-modifying 
drug with additional bronchodilator properties would represent a major advance for 
managing young patients with asthma (Wenzel 1998; Warner 2001).
Leukotriene modiﬁ  ers are an entirely new class of drugs for the treatment of asthma. 
We now know that asthma is basically a disorder of airway inﬂ  ammation. The last few Therapeutics and Clinical Risk Management 2007:3(5) 886
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years have seen extensive research on mediators of inﬂ  amma-
tion, including leukotrienes, prostaglandins, neuropeptides, 
lymphokines, and interleukins. The knowledge gained about 
these mediators is being put to use to develop new drugs 
for this old afﬂ  iction of mankind. Montelukast is one of the 
results of this scientiﬁ  c search (Salvi et al 2001).
Leukotriene modiﬁ  ers (LTRs)
Leukotrienes are chemical mediators of asthmatic airway 
inﬂ  ammation (Figure 1). They are formed from arachidonic 
acid, and are secreted by eosinophils, mast cells, neutrophils, 
lymphocytes, macrophages, and basophils (Turner et al 
1996) (Figure 2). After the discovery in the late 1970s that 
the cysteinyl leukotrienes LTC4 and LTE4 (formerly known 
collectively as the slow-reacting substance of anaphylaxis 
[SRS-A]) play a key role in the pathophysiology of asthma 
a number of speciﬁ  c antagonists of their actions have been 
developed. The leukotriene receptor antagonists (LTRAs) 
selectively block the binding of cysteinyl leukotrienes to the 
CysLT1 receptor, which has been identiﬁ  ed as the receptor 
through which most of their actions are mediated (Drazen 
et al 1999). These actions include bronchoconstriction, 
mucus hypersecretion, and increased vascular permeability 
and eosinophil migration. Consequently, the LTRs inhibit 
bronchconstriction. Moreover, LTRAs prevent many types 
of provoked asthmatic responses, including allergen-induced, 
exercise- and cold-air-hyperventilation-induced, and aspi-
rin-induced asthma (Wright et al 1998). Three drugs of 
this class are in use at present – zaﬁ  rlukast, pranlukast, and 
montelukast. All three are speciﬁ  cally active against the 
cysteinyl leukotrienes by blocking their receptor, CysLT1. 
Only montelukast has been extensively studied in children 
(Jones et al 1995).
Montelukast
Montelukast (Merck and Co, Inc, Whitehouse Station, NJ) 
is an orally bioavailable Cys-LTRA administered once daily 
(Noonan et al 1998). The drug has been approved for the 
treatment of asthma in children 6 months and older (Skoner 
2001). There is no difference in bioavailability in young and 
elderly patients, and food does not have a clinically important 
inﬂ  uence with chronic administration (Altman et al 1998). 
Therapeutic concentrations of montelukast do not inhibit the 
cytochrome P450 isoenzymes. Dose-ranging studies evaluat-
ing multiple doses and dosage schedules of montelukast have 
been reported in adults with chronic asthma (Bisgaard 2001). 
These studies have evaluated measures of asthma control, 
including lung function, use of rescue treatment, and symptom 
scores. Doses of 10 to 200 mg had similar efﬁ  cacy, while 
2 mg produced suboptimal response. BID dosing provided 
no additional beneﬁ  t over once-daily dosing (Altman et al 
1998). The bronchoprotective effect against exercise-induced 
bronchoconstriction (EIB) was also dose-related up to 10 mg 
in adult asthmatics, and there was no additional improvement 
with higher doses (Bronsky et al 1997). Dose-ranging studies 
have not been performed in children. Instead, the pediatric 
dosage was chosen as the dosage yielding a pharmacokinetic 
proﬁ  le (single-dose area under the plasma concentration-time 
curve) in children comparable to that achieved with the 10-mg 
tablet in adults (Knorr et al 1999).
Adverse effects of montelukast 
Pediatric studies on montelukast found that it was well toler-
ated. The majority of the reported adverse effects were mild 
and included headache, ear infection, nausea, abdominal 
pain, and pharyngitis. In clinical trials the incidence of these 
adverse effects was not higher than with placebo (Bisgaard 
2001). No dose adjustment with montelukast is necessary for 
patients with renal and mild-moderate hepatic dysfunction 
(Salvi et al 2001).
Montelukast for managing childhood 
asthma: compared with placebo
Several randomized double blind comparative studies in 
pediatric patients have compared therapeutic efﬁ  cacy of 
montelukast and placebo (Knorr et al 2001a, b; Strauch 
et al 2003; Becker et al 2004; Bisgaard 2005) (Table 1). The 
asthma severity was mild to moderate persistent in these 
trials. The results from these studies depicted signiﬁ  cant 
improvements in multiple parameters of asthma control 
with montelukast compared to placebo: day-time asthma 
symptoms (cough, wheeze, breathing difficulty, and 
activity limitation), overnight asthma symptoms (cough); 
percentage of days with asthma symptoms, percentage of 
days without asthma, need for beta-agonist or oral cortico-
steroids; physician global evaluations and peripheral blood 
eosinophils. There was a signiﬁ  cantly greater improvement 
in forced expiratory volume in 1 second (FEV1) from base-
line for the montelukast group compared to placebo group. 
Studies comparing the effect on fractional exhaled nitric 
oxide (FeNO), a marker of airway inﬂ  ammation in asthma, 
found a signiﬁ  cant reduction in FeNO in the montelukast 
arm (Bisgaard et al 1999). A recent study conducted among 
preschool children revealed that 4 weeks treatment with 
montelukast resulted in a decrease in bronchial hyperreac-
tivity compared with placebo (Hakim et al 2007).Therapeutics and Clinical Risk Management 2007:3(5) 887
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Epidemiologic studies have detected viral upper respira-
tory tract ınfections (URTIs) in 85% of childhood asthma 
exacerbations. Cycteinyl leukotrienes are released during 
infection with respiratory syncytial virus infection in infants 
and in virus-associated wheeze in preschool children. Cys-
teinyl leukotrienes appear to mediate abnormalities of lung 
function, including mucus production, decreased mucocili-
ary clearence, changes in vascular permeability, and smooth 
muscle contraction. Montelukast is an oral speciﬁ  c cysteinyl 
LTRA with bronchoprotective effects for 20–24 hours after 
dosing (Robertson et al 2007). In this regard it was reported 
that 12 months of treatment with montelukast decreased 
viral-induced attacks of preschool children with intermittent 
asthma (Bisgaard et al 2005).
Montelukast for managing childhood asthma: 
compared with inhaled corticosteroids
Many studies have compared leukotriene inhibitors with 
other asthma treatments. Two Cochrane Reviews evaluated 
research comparing leukotriene inhibitors with inhaled cor-
ticosteroids in the management of recurrent and persistent 
asthma in children (Ducharme and Di Salvio 2002; Ng et al 
2004). Ducharme and Di Salvio conducted a bibliographic 
search of randomized controlled clinical trials comparing 
Figure 1 Pathogenesis of airway obstruction in asthma.
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the efﬁ  cacy of antileukotrienes with inhaled corticosteroids 
(ICSs) in asthmatic patients and identiﬁ  ed 27 trials of which 
13 were of high methodological quality. Mild-to-moderate 
chronic asthmatic patients treated with LTRAs were 60% 
more likely to experience an asthma exacerbation requiring 
oral steroids than those treated with ICSs (in most trials the 
daily dose of ICSs was 400 mg of beclomethasone or equiva-
lent). After 6 weeks of treatment, those patients who received 
ICS showed a signiﬁ  cantly greater improvement in baseline 
FEV1, morning peak expiratory ﬂ  ow rate, fewer nocturnal 
awakenings and respiratory symptoms, and less use of rescue 
medication. Ng et al (2004) conﬁ  rmed the earlier ﬁ  ndings 
by Ducharme and Di Salvio that patients on antileukotrienes 
are more likely to suffer an exacerbation requiring systemic 
steroids, to exhibit a lesser improvement in lung function, and 
to report more nocturnal awakenings and respiratory symp-
toms and greater use of rescue medication. The available 
evidence convincingly persuades against the use of LTRAs 
as ﬁ  rst-line monotherapy in patients with mild-to-moderate 
asthma (Table 2). It must be noted that only 3 of the 13 studies 
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Figure 2 Schematic representation of the arachidonic acid cascade. LTC4 is generated by the action of 5-LO on cell membrane-derived arachidonic acid. It is rapidly 
converted to the equipotent LTD4 and then to the stable excretory product LTE4.Therapeutics and Clinical Risk Management 2007:3(5) 889
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taken in the meta-analysis were conducted among children. 
With only 3 published trials for a total of 216 patients, there 
is insufﬁ  cient evidence to make any ﬁ  rm conclusions about 
the use of LTRAs as monotherapy in children with asthma 
(Table 2). LTRAs appear to be safe. At present, the scientiﬁ  c 
evidence does not support the substitution of LTRA for low 
doses of ICSs, which remain the ﬁ  rst-line therapy for asthma 
(Ducharme 2004).
Montelukast for managing childhood 
asthma: compared with long-acting
beta-2 agonists (LABA) as add-on
therapy to ICSs
Pediatric studies comparing montelukast with LABA as 
add-on therapy to ICSs in persistent asthma are limited. 
One study by (Buchvald et al 2003) found that FeNO levels 
were signiﬁ  cantly higher after salmeterol add on treatment 
compared with both placebo and montelukast. FEV1 levels 
were comparable between the two groups. Another study by 
Bjermer et al (2000) revealed that adddition of montelukast 
in patients whose symptoms remain uncontrolled by ICSs 
could provide equivalent clinical control to salmeterol. Ram 
et al (2005) recently summarized the addition of a LABA 
compared with a LTRA in patients receiving inhaled steroids. 
This study concluded that in adults with asthma inadequately 
controlled by low-dose inhaled steroids, the addition of a 
LABA was superior in preventing exacerbations requiring 
systemic steroids.
The only study conducted among children is a very recent 
report which has revealed that add on therapy with montelu-
kast plus low-dose budesonide was more effective than the 
addition of LABA or doubling the dose budesonide for con-
trolling FeNO in asthmatic children (Miraglia et al 2007).
Exercise-induced asthma
During exercise, evaporation of water from the airway surface 
is the stimulus for release of inﬂ  ammatory mediators such as 
histamine and cysteinyl leukotrienes (Stelmach et al 2004). 
Current options for attenuating exercise-induced asthma are 
inhaled beta agonists, cromolyn, or oral theophylline. All of 
these, with the exception of LABA, must be taken shortly 
before starting the exercise activity, and they provide pro-
tection for 1–2 hours only (Pearlman et al 1999). Exhaled 
breath condensate Cys-LT values are shown to be higher in 
asthmatic children with EIB and correlate with the dicrease in 
FEV1 after exercise (Carraro et al 2005). LTRAs are reported 
to decrease exhaled LTE4 in atopic children with asthma 
(Montuschi et al 2006). Accordingly, montelukast was shown 
to be effective in controlling asthma symptoms after exercise 
in children. Speciﬁ  cally, it is approved for the prevention 
of EIB from 2 years of age (Pajaron-Fernandez et al 2006). 
Table 1 Studies comparing the efﬁ  cacy of montelukast vs placebo in childhood asthma
Study  Design   Study   Intervention  Main outcome   Conclusions 
   population    measures 
Bisgaard et al   RCT,   2–5 y (n = 549)  MT (4 or 5 mg)  Asthma   Reduced
2005  DB  intermittent   vs placebo, 12 mo  exacerbation   exacerbation
   asthma      episodes
Becker et al   RCT,   6–14 y (n = 138)   MT (5 mg) vs   % change   Signiﬁ  cant
2004  DB  mild persistent   placebo 8 wk  FEV1 improvement
    asthma      (p = 0.005)
Strauch et al   RCT  6–14 y (n = 25)   MT (5 mg) vs   Sputum ECP,   MT suppressed
2003    steroid-  placebo 4 wk  sputum Eo   sputum ECP,
    dependent     count, FeNO,   improved QOL,
    asthma    QOL  no change in
         rest  of
         parameters
Knorr et al   RCT,   2–5 y (n = 689)   MT vs   Clinical   Clinically
2001b  DB  persistent   placebo, 12 wk  parameters of   signiﬁ  cant,
    asthma    asthma control,   efﬁ  cacy well
       Adverse  effects,  tolerated
       QOL  scores
Knorr et al   RCT,   6–14 y (n = 336)   MT (5 mg) vs   Morning FEV1   Signiﬁ  cant 
1998  DB  persistent   placebo 8 wk  change  improvement 
   asthma      (p  < 0.001)
Abbrevations: DB, double-blind; ECP, eosinophilic cationic protein; FeNO, fractional exhaled nitric oxide; RCT, randomized control trial; MT, montelukast; QOL, quality of life.Therapeutics and Clinical Risk Management 2007:3(5) 890
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Notably, over an 8-week study period, the tolerance that some 
patients developed to LABA did not occur in patients receiv-
ing leukotriene inhibitors (Edelman et al 2000). One review 
suggests that using leukotriene inhibitors may be preferable 
to increasing the dose of beta-2 agonists (Anderson 2004). 
Leukotriene inhibitors can provide a useful alternative in 
preventing exercise-induced asthma, especially in young 
children for whom the use of an inhaler may be difﬁ  cult, or 
for persons who receive incomplete protection from short-
acting beta-2 agonists (Thomas et al 2007).
Aspirin-induced asthma
The cysteinyl leukotrienes are the leading mediators of the 
airway reaction that occurs in persons with aspirin-sensitive 
asthma after exposure to aspirin (O’Byrne et al 1997). LTRs 
resulted in almost complete inhibition of aspirin-induced bron-
choconstriction as well as symptoms of the skin and gastrointes-
tinal tract (Israel et al 1993). For this reason LTRs are able to 
prevent this reaction (Drazen et al 1999) and are the treatment 
of choice for these patients (Wenzel 1998; Mehta 2000).
Predicting the response to montelukast
Heterogeneous response has been documented for asthma 
treatments, including LTRAs (Meyer et al 2003). This issue is 
further complicated in young children who present with asthma-
like symptoms that might represent other disease pathologies. 
Therefore it is a critical clinical question whether a particular 
therapy will be effective in an individual child with symptoms 
of asthma, and examination of this question is pertinent.
Studies have demonstrated that genetic variation in some 
genes encoding key proteins in the leukotriene pathway 
(ALOX5, LTA4H, LTC4S, and ABCC1) inﬂ  uences response 
to LTRAs. Also plasma concentrations of LTRAs vary consid-
erably among patients. Physiochemical characteristics make it 
likely that membrane efﬂ  ux and update transporters mediate 
the absorbtion of LTRAs into the systemic circulation follow-
ing oral administration. Genes that encode efﬂ  ux and uptake 
transport proteins harbor many varients that could inﬂ  uence 
the pharmacocinetics, and particularly the bioavailability of 
LTRAs, and could contribute to heterogeneity in response.
Efforts to determine clinical indicators of response to 
LTRAs have not been very successful. Results from a primary 
trial analysis of 2- to 5-year-old patients indicated no differ-
ence in response to montelukast according to study center, 
age, sex, or race. In another study among 6- to 14-year-old 
patients, no treatment differences were observed according 
to categories of age, ethnicity, Tanner stage, or history of 
exercise-induced asthma. Additionally, in subjects aged 15 
years or older, baseline peak expiratory ﬂ  ow variability was 
not associated with montelukast-associated decreases in peak 
expiratory ﬂ  ow variability over follow-up. The ﬁ  ndings of a 
recent study demonstrated that characteristics predictive of 
asthma prognosis (such as family history of asthma, eosino-
philia, and personal history of allergy) were not, in general, 
predictive of response to montelukast.
Studies have demonstrated that some clinical indicators 
can predict a better clinical response to inhaled corticosteroids 
compared with LTRAs. Intra-individual analyses revealed 
lower levels of pulmonary function, greater bronchodila-
tor use, and higher levels of biomarkers of inﬂ  ammation, 
including FeNO, at baseline related to a better differential 
pulmonary response to ICSs compared with montelukast 
(Szeﬂ  er 2005). The report of Zeiger et al (2006) extends the 
ﬁ  ndings of this study to several other measures of asthma 
control, including asthma control days. Strong evidence of 
greater mean improvements after 8 weeks of therapy with an 
ICS compared with an LTRA across many other outcomes 
(asthma control days, asthma control questionnaire score, 
albuterol use, FeNO, peak expiratory ﬂ  ow rate variability, 
morning peak expiratory ﬂ  ow rate, and measures of imped-
ance). FeNO, as a predictor of clinical and pulmonary 
responses, might be a useful marker to identify individual 
Table 2 Studies comparing efﬁ  cacy of montelukast and ınhaled corticosteroids in childhood asthma
Study  Study population   Intervention  Main outcome  Conclusions
    measures
Stelmach et al 2004  Children (n = 51)  MT vs Inh BD 6 mo  IgE  Inh BD and MT
        decreased S IgE levels
Garcia et al 2005  6–14 years  MT vs Inh FP 12 mo  FeV1  Those with low pulmonary
 Children  (n  = 914)      function, high markers,
      better  response  to  FP
Maspero et al 2001  10 years children  MT vs BDP, 6 mo  FeV1  MT = BDP
 (n  = 124)
Abbreviations: BD, budesonide; BDP, beclomethasone dipropionate; FEV1, forced expiratory volume in 1 s; FP, ﬂ  uticasone propionate; ICS, inhaled corticosteroid; MT, 
montelukast; PEFR, peak expiratory ﬂ  ow rate.Therapeutics and Clinical Risk Management 2007:3(5) 891
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children solely receiving as-needed bronchodilators who 
achieve a greater improvement in asthma control days (pres-
ent study) and FEV1 with an ICS compared with a LTRA 
(Zeiger et al 2006).
LTRAs decrease exhaled LTE4 in atopic children with 
asthma. This reduction is dependent on baseline exhaled 
LTE4 values. Measurement of exhaled LTE4 might help 
identify children with asthma most likely to beneﬁ  t from 
LTRAs (Montuschi et al 2006).
Position of montelukast in current 
pediatric asthma management guidelines
The international guideline for asthma mangement, GINA 
(Global INiative for Asthma) was updated at 2006. In this 
reviewed addition, asthma treatment is based on “asthma 
control” and has 5 steps (Global Strategy for Asthma 
Management and Prevention, 1995 updated 2006). For 
children whose asthma is partially controlled with only 
short-acting bronchodilators, LTRAs are recommended as 
an alternative to low-dose ICSs (in step 2). In step 3, adding 
LTRA to low-dose ICSs is given as an alternative to using 
other add-on therapies. In this guideline, it is stated that the 
available literature on treatment of asthma in children 5 years 
and younger precludes detailed treatment recommendations. 
The best-documented treatment to control asthma in these age 
groups is ICSs and at Step 2, a low-dose inhaled glucocortico-
steroid is recommended as the initial controller treatment.
British Thoracic Society (BTS) Guidelines, updated in 
2006, give special recommendations for children under 5 
years. According to this guideline, LTRAs can be used as 
a regular preventive therapy when ICSs cannot be used or 
as an add on therapy when disease is not under control with 
200–400 µg ICSs. For children under 2 years, it is recom-
mended to refer the patient to a respiratory pediatrician 
before adding LTRAs. For children over 5 years, LTRAs are 
recommended when ICSs cannot be used and as an add-on 
treatment when only a good response to LABA cannot be 
achieved, LABAs are recommended as the ﬁ  rst choice of 
add on therapy for this group of children.
Conclusion
The current evidence indicates that ﬁ  rst-line monotherapy 
with antileukotrienes is not generally recommended in 
asthma sufferers, with perhaps the exclusion of those who 
have aspirin-intolerant asthma and exercise-induced asthma. 
Its efﬁ  cacy and cost-effectiveness in comparison to ICSs for 
the management of mild persistent asthma is inferior, but 
there are studies supporting that adddition of montelukast in 
patients whose symptoms remain uncontrolled by ICSs could 
provide equivalent clinical control to salmeterol (Bjermer 
et al 2000; Miraglia et al 2007). Nonetheless, by virtue of 
their high systemic bioavailability, antileukotrienes may 
be valuable in those asthmatic patients who ﬁ  nd it difﬁ  cult 
to use inhaled medications. In summary, Cys-LTRAs have 
proved moderately effective in asthmatic children, an effect 
which appears to be complementary to current corticosteroid 
treatment.
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